EU has approved Secukinumab (Cosentyx) for use in pediatric plaque psoriasis - moderate-to-severe psoriasis affects more than 350,000 children worldwide. Approval is based on 2 phase 2 wo international in children 6 to <18 years. https://t.co/Y05ElRr6xn